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Objective. To develop and validate a composite disease activity score for juvenile idiopathic arthritis (JIA), the Juvenile
Arthritis Disease Activity Score (JADAS).
Methods. The JADAS includes 4 measures: physician global assessment of disease activity, parent/patient global assess-
ment of well-being, active joint count, and erythrocyte sedimentation rate. These variables are part of the American
College of Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 50, and Pedi 70 criteria for improvement. Validation analyses
were conducted on >4,500 patients and included assessment of construct validity, discriminant validity, and respon-
siveness to change. Three versions of the JADAS were tested based on 71-joint (range 0–101), 27-joint (range 0–57), or
10-joint (range 0–40) counts. Statistical performances of the JADAS were compared with those of 2 rheumatoid arthritis
composite scores, the Disease Activity Score in 28 joints (DAS28) and the Clinical Disease Activity Index (CDAI).
Results. The JADAS demonstrated good construct validity, yielding strong correlations with JIA activity measures not
included in the score and moderate correlations with the Childhood Health Assessment Questionnaire. Correlations
obtained for the 3 JADAS versions were comparable, but superior to those yielded by the DAS28 and CDAI. The area
under the curve of the JADAS predicted long-term disease outcome, measured as radiographic progression over 3 years.
In 2 clinical trials, the JADAS discriminated well between ACR Pedi 30, Pedi 50, and Pedi 70 response and revealed strong
responsiveness to clinical change.
Conclusion. The JADAS was found to be a valid instrument for assessment of disease activity in JIA and is potentially
applicable in standard clinical care, observational studies, and clinical trials.
INTRODUCTION
Juvenile idiopathic arthritis (JIA) is a chronic inflamma-
tory disease with a widely variable clinical course and
outcome (1). Evaluation of disease activity is a fundamen-
tal component of the clinical assessment of children with
JIA because persistently active disease plays a major role
in causing joint damage and physical functional disability.
Furthermore, measurement of the level of disease activity
over time is important in assessing the effectiveness of
antirheumatic drugs in clinical trials and in monitoring
the patient’s course in daily care.
A variety of instruments are available for measuring
disease activity in JIA, including global assessment scales,
pain measures, various types of joint counts, functional
ability questionnaires, acute-phase reactants, and even
more general measures, such as hemoglobin level, white
blood cell count, platelet count, serum immunoglobulin
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level, body weight, and requirement for increasing medi-
cations. However, due to the high variability in the clinical
presentation and course of JIA, no single measure can
reliably capture disease activity in all patients. Con-
versely, evaluation of all measures individually is associ-
ated with methodologic and statistical problems, espe-
cially when these measures are employed as end points in
clinical trials. Measures of disease activity, which assess
the signs and symptoms related to inflammation, should
be separated from measures of disease severity, such as
those that assess functional impairment and structural
joint damage.
To achieve a more rational and standardized approach, a
core set of variables to be used in JIA disease activity
assessment has been established by the American College
of Rheumatology (ACR) (2). This core set is composed of
the following 6 measures: physician global assessment of
disease activity, parent/patient global assessment of well-
being, active joint count, restricted joint count, functional
assessment, and a laboratory measure of inflammation.
Using this core set, a definition of improvement in JIA was
developed (the ACR Pediatric 30 [Pedi 30], Pedi 50, and
Pedi 70 criteria for improvement) (2).
The ACR Pedi 30, Pedi 50, and Pedi 70 response criteria
emphasize change in disease state and, therefore, are a tool
for assessment of clinically relevant improvement in dis-
ease activity. However, the nature of their calculation does
not enable the measurement of actual disease activity or
the comparison of one patient’s absolute response with
that of another patient’s. Furthermore, they do not allow
discernment of whether one group of patients has more
active disease than another group.
Similar considerations in adult rheumatology conferred
a rationale for pooling individual measures of disease ac-
tivity into composite scores. These tools were aimed to
quantify the absolute level of disease activity by providing
one summary number on a continuous scale. A number of
such scores have been developed for rheumatoid arthritis
(RA), including the Disease Activity Score (3), the Disease
Activity Score in 28 joints (DAS28) (4), the Simplified
Disease Activity Index (5), and the Clinical Disease Activ-
ity Index (CDAI) (6). These measures have the advantage of
creating better consistency in disease activity evaluation
across physicians, of allowing patients to better under-
stand the meaning of disease activity by providing a single
score number, and of reducing the sample size require-
ment in clinical trials (7). Composite disease activity
scores can be used in the assessment of therapeutic effi-
cacy in clinical trials and in monitoring disease activity in
individual patients in standard clinical practice.
At present, such measures do not exist for JIA. For this
reason, the purpose of the present study was to develop
and validate a composite disease activity score for JIA,
called the Juvenile Arthritis Disease Activity Score
(JADAS).
PATIENTS AND METHODS
Development of the JADAS. The composite disease ac-
tivity score for JIA was devised by a panel of 9 pediatric
rheumatologists (AC, NR, AB, SM-M, GF, CM, SV, AM,
and AR) with 2 to 20 years of clinical experience in the
field, who reached consensus on the individual measures
to be included in the score. Investigators were asked to
base their choice on their clinical experience and on a
review of the pertinent literature. All investigators agreed
that the components of the JADAS should be selected from
the 6 variables included in the ACR Pedi 30, Pedi 50, and
Pedi 70 core set (2). However, it was felt that 2 of the 6
variables, restricted joint count and functional assessment,
were not suited for inclusion in the JADAS because they
are affected by disease damage (functional or structural)
(8). Functional status assessment was not included be-
cause it has been shown to be relatively insensitive to
change in JIA (9–12). The parent global assessment was
also found to reflect functional damage, particularly in the
later stages of illness (8). However, it was believed impor-
tant to include this parameter in order to incorporate par-
ents’ perception of disease activity. The physician global
assessment was included because it represents the most
responsive measure in JIA (9–11).
Other measures were also considered. Pain rating was
discarded because it is reflected in the parent/patient
global assessment. The swollen and tender joint counts
were not included because they are highly correlated with
active joint count (8,13,14). Although health-related qual-
ity of life (HRQOL) is largely driven by the disease process,
it is influenced by many external factors. Therefore,
HRQOL-related questionnaires were not thought to mea-
sure disease activity reliably.
The final version of the JADAS that was agreed upon by
the study panel included the following 4 measures: phy-
sician global assessment of disease activity, measured on a
10-cm visual analog scale (VAS) where 0  no activity and
10  maximum activity; parent/patient global assessment
of well-being, measured on a 10-cm VAS where 0  very
well and 10  very poor; count of joints with active dis-
ease; and erythrocyte sedimentation rate (ESR). The choice
of ESR instead of C-reactive protein (CRP) level was dic-
tated by its availability as a sole acute-phase reactant in
most study data sets (see below).
To substantiate that the combination of these variables
truly measures a single construct, e.g., disease activity,
principal component analysis was performed on the 6 core
set variables plus the parent assessment of pain and the
swollen and tender joint counts. This analysis was done
on a HRQOL study and on a methotrexate (MTX) trial (see
below). Two factors with eigenvalues 1 and a cumulative
percentage of explained variance of 66% were identified.
The first factor included the joint counts, and the second
factor included the physician’s and parent’s subjective
assessments, the Childhood Health Assessment Question-
naire (C-HAQ), and ESR (data not shown). These findings
supported the choice of the selected variables as measures
of disease activity.
Based on a previous analysis that showed that the 27-
joint reduced count is a good surrogate for the whole joint
count in JIA (15), it was decided, due to its greater
feasibility, to incorporate this reduced count (named the
JADAS-27) in the JADAS. The JADAS-27 includes the
following joints: cervical spine, elbows, wrists, meta-
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carpophalangeal joints (from first to third), proximal inter-
phalangeal joints, hips, knees, and ankles. Two additional
versions of the JADAS, one including the entire 71 joints
(JADAS-71) and one including a 10-joint reduced count
(JADAS-10; based on the count of any involved joint, irre-
spective of its type, up to a maximum of 10 joints), were
tested in the validation analyses.
The ESR value was normalized to a 0–10 scale according
to the following formula:
ESRmm/hour  20
10
Before making the calculation, ESR values 20 mm/hour
were converted to 0 and ESR values 120 mm/hour were
converted to 120.
The JADAS was calculated as the simple linear sum of
the scores of its 4 components, which yields a global score
of 0–57, 0–101, and 0–40 for the JADAS-27, JADAS-71,
and JADAS-10, respectively.
The study protocol was approved by the Ethics Commit-
tee of the Istituto G. Gaslini, Genoa, Italy.
Study data sets. Four samples composed of patients
meeting the International League of Associations for Rheu-
matology criteria for JIA (16) were used to validate the
JADAS. The first was a cross-sectional sample of 434 un-
selected patients who underwent a clinic visit in the au-
thors’ units between 2002 and 2007. The second sample
was also cross-sectional and included 3,324 patients en-
rolled in a study on HRQOL by the Paediatric Rheumatol-
ogy International Trials Organisation (17). The third sam-
ple was composed of 595 patients with polyarthritis
included in a controlled trial that compared intermediate
versus higher doses of MTX (18). The fourth sample com-
prised 225 patients with oligoarthritis or polyarthritis in-
cluded in a controlled trial that compared meloxicam with
naproxen (19). The unselected clinic patients included all
JIA subtypes, but patients with rheumatoid factor (RF)–
positive polyarthritis were excluded from the MTX trial,
and patients with psoriatic arthritis and enthesitis-related
arthritis were excluded from the HRQOL study, the MTX
trial, and the meloxicam/naproxen trial.
Validation procedures. Validation of the JADAS was
based on evaluation of construct validity, discriminant
validity, and responsiveness to change. In all analyses, the
statistical performances of the JADAS were compared with
those of 2 RA disease activity scores: the DAS28 (4) and
the CDAI (6). The individual elements included in the
composite scores were examined and their theoretical
ranges are presented in Table 1. In all scores, the parent
global rating was used as a substitute for the patient global
assessment, because the latter measure was available for
only a few observations.
Construct validity is a form of validation that examines
whether the construct in question, in this case the JADAS,
is related to other measures in a manner consistent with a
priori prediction. Given that the JADAS was devised to
measure JIA activity, it was predicted that its correlation
with swollen and tender joint counts would be high, be-
cause both are measures of closely related constructs. Cor-
relations with parent rating of pain intensity, C-HAQ score
(20), and restricted joint count were predicted to be mod-
erate because these measures combine the effect of both
disease activity and damage. Correlations with CRP level
were also predicted to be moderate because it is known
that clinical measures of disease activity correlate only
moderately with acute-phase reactants (8,14). It was antic-
ipated that correlations for the JADAS would be similar to
those for the DAS28 and the CDAI because these scores
measure the same construct.
Construct validity of the JADAS was further evaluated
by examining its correlation with radiographic progres-
sion. Sufficient clinical data were available for 60 of the
103 patients included in a recent study on the validation of
adapted versions of the Sharp/van der Heijde score in
patients with JIA (21) who had wrist/hand radiographs
performed at first observation and after 3 years. Correlation
between the area under the curve of the JADAS and the
observed changes in radiographic score over 3 years was
Table 1. Composition and theoretical range of the composite disease activity scores tested in the study*
JADAS-71 JADAS-27 JADAS-10 DAS28 CDAI
Physician global
assessment
0–10-cm VAS 0–10-cm VAS 0–10-cm VAS – 0–10-cm VAS
Parent/patient global
assessment
0–10-cm VAS 0–10-cm VAS 0–10-cm VAS 0–1.40-mm VAS 0–10-cm VAS
Active joint count Simple, 0–71 joints Simple, 0–27 joints Simple, 0–10 joints† – –
Swollen joint count
(range)



















Score range 0–101 0–57 0–40 0.49–9.07 0–76
* JADAS-71  Juvenile Arthritis Disease Activity Score in 71 joints; DAS28  Disease Activity Score in 28 joints; CDAI  Clinical Disease Activity
Index; VAS  visual analog scale; ESR  erythrocyte sedimentation rate.
† Up to 10 joints, irrespective of their type, censored at 10.
‡ According to the formula: (value in mm/hour 20)/10, where values 20 mm/hour are converted to 0, and values 120 mm/hour are converted to
120.
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computed. Only the JADAS-71 and JADAS-10 could be
assessed because the type of joints involved over time was
not known. All correlations were calculated using Spear-
man’s rank statistics. Correlations were considered high,
moderate, or strong at 0.7, 0.4–0.7, or 0.4, respectively
(25).
For the assessment of discriminant validity, we charac-
terized patients by their degree of improvement according
to the ACR Pedi 30, Pedi 50, and Pedi 70 response criteria
(2) in the 2 clinical trials. Patients were divided by their
maximum level of improvement at 6 and 3 months, respec-
tively, into 4 mutually exclusive groups: nonresponders,
Pedi 30 responders, Pedi 50 responders, and Pedi 70 re-
sponders. Using one-way analysis of variance, we ana-
lyzed whether changes in JADAS were greater in ACR Pedi
50 and Pedi 70 response groups, and whether these differ-
ences were statistically significant at a group level. Com-
parisons of quantitative variables among groups were
made by means of the nonparametric analysis of variance
(the Kruskal-Wallis nonparametric test); Dunn’s test was
chosen as a posteriori test to assess the statistical signifi-
cance of differences between pairs of patient groups.
The responsiveness to change of the disease activity
scores was assessed by computing the standardized re-
sponse mean (SRM) in the 2 clinical trials. The SRM was
calculated as the mean baseline-to-end point change in
score divided by the SD of the individual’s change in score
(23). In line with Cohen (24), the threshold levels for SRM
were defined as follows: 0.20  small, 0.50  moder-
ate, and 0.80  good. Distribution of composite scores
was examined by assessing their skewness and kurtosis. In
the case of normal distribution, the value of these param-
eters will be 0.
All statistical tests were 2-sided, and P values less than
0.05 were considered statistically significant. The statisti-
cal packages used were Statistica (StatSoft, Tulsa, OK) and
Stata, version 7 (Stata Corporation, College Station, TX).
RESULTS
The main demographic and clinical features of the 4 pa-
tient samples are shown in Table 2.
Construct validity. Correlations on cross-sectional data.
The Spearman’s correlations between the JIA clinical
measures that were not incorporated in the scores of the
cross-sectional patient samples and the 3 JADAS versions,
the DAS28, and the CDAI are presented in Table 3. Over-
all, correlations were better for clinic patients and HRQOL
study patients than they were for clinical trial patients. As
predicted, JADAS correlations with joint counts were in
the moderate-to-high range, whereas correlations with
parent pain rating, C-HAQ score, and CRP level were
moderate. Also as predicted, restricted joint count was
correlated with JADAS at a lower level as compared with
swollen joint count. Correlations yielded by the JADAS-71
were similar to those yielded by the versions based on
reduced joint counts, with the exception of the poorer
correlations between the JADAS-10 and swollen, tender,
and restricted joint counts in the MTX trial. In general,








trial† (n  225)
No. Median (IQR) No. Median (IQR) No. Median (IQR) No. Median (IQR)
Age at disease onset, years 434 3.4 (1.9–6.0) 3,114 5.2 (2.6–8.7) 592 4.4 (2.0–8.5) – 5.0 (2–8)
Age at study visit, years 434 7.2 (3.9–11.2) 3,141 10.6 (7.2–14) 595 7.8 (4.2–11.3) 225 8.0 (5–12)
Disease duration, years 434 2 (0.8–5.4) 3,115 3.8 (1.6–6.7) 592 1.1 (0.4–3.4) – 1.8 (0.5–4)
Swollen joint count 425 2 (0–3) 2,768 1 (0–4) 594 7 (4–13) 225 3 (2–6)
Tender joint count 425 1 (0–3) 2,768 1 (0–3) 594 7 (4–14) 225 3 (2–6)
Restricted joint count 425 1 (0–3) 2,768 2 (0–7) 594 8 (5–14) 225 3 (2–7)
Active joint count 425 2 (0–4) 2,768 2 (0–5) 594 9 (6–16) 225 4 (2–7)
Physician global assessment‡ 400 3.4 (0.0–7.3) 2,758 1.8 (0.4–3.9) 590 5.1 (3.7–6.6) 225 3.4 (2.2–5.3)
Parent global assessment‡ 225 1 (0.0–3.7) 2,853 1.4 (0.1–4.2) 591 4.5 (2.2–6.3) 225 3.5 (2.2–5.2)
Parent pain assessment‡ 225 1 (0.0–3.7) 2,849 1.4 (0.1–4.1) 589 4.5 (2.4–6.9) – –
C-HAQ score§ 232 0.1 (0.0–0.3) 2,857 0.38 (0.0–1.12) 592 1.25 (0.62–1.75) 225 0.62 (0.25–1.25)
ESR, mm/hour¶ 306 15 (9–38) 2,450 20 (10–38) 581 40 (22–62) 218 12.0 (6.6–25)
CRP level, mg/dl# 227 0.5 (0.4–1.5) – – – – – –
JADAS-71 207 4.5 (0.6–12.5) 2,424 7.5 (2.9–15.3) 573 22.1 (16.1–29.9) 218 11.9 (8.3–18.2)
JADAS-27 207 4.5 (0.5–11.2) 2,424 7.2 (2.8–14.3) 573 20.4 (15.1–26.5) 218 11.5 (8.0–17.5)
JADAS-10 207 4.5 (0.6–12.5) 2,424 7.5 (2.9–14.7) 573 19.7 (15.8–24.5) 218 11.9 (8.3–17.3)
DAS28 211 2.5 (1.8–3.7) 2,438 3.0 (2.0–4.1) 577 5.0 (4.3–5.8) 218 3.5 (2.8–4.3)
CDAI score 221 5.0 (1.0–12.6) 2,725 6.2 (2.1–12.6) 587 19.4 (14.3–29.7) 225 11.4 (8.0–17.9)
* HRQOL  health-related quality of life; IQR  interquartile range; C-HAQ  Childhood Health Assessment Questionnaire; CRP  C-reactive protein.
See Table 1 for additional definitions.
† At baseline.
‡ Range 0 (best) to 10 (worst).
§ Range 0 (best) to 3 (worst).
¶ Normal at 20 mm/hour.
# Normal 0.46 mg/dl.
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correlations yielded by the DAS28 and CDAI were lower
than those yielded by the JADAS.
Changes in JADAS in relation to changes in C-HAQ,
DAS28, and CDAI scores. The Spearman’s correlations
observed for score changes in clinical trials are shown in
Table 4. As expected, JADAS correlations with C-HAQ
scores were moderate, whereas JADAS correlations with
DAS28 and CDAI scores were high. Correlations were
comparable across JADAS versions, except for correlations
between the JADAS-10 and the CDAI, which were lower
than those yielded by the JADAS-71 and JADAS-27. Cor-
relations with C-HAQ scores were higher for the JADAS
than for the DAS28 and CDAI.
Relationship with radiographic outcome. Spearman’s
correlation between the area under the curve of JADAS
disease activity and the changes in adapted total Sharp/
van der Heijde score over 3 years were moderate (rs  0.47
for the JADAS-71 and rs  0.50 for the JADAS-10). Both
correlations were highly significant (P  0.001), therefore
demonstrating that the composite score predicts radio-
graphic progression.
Discriminant validity: changes in JADAS in relation to
ACR Pedi 30, Pedi 50, and Pedi 70 response. In the MTX
trial, the percentages of nonresponders and ACR Pedi 30,
Pedi 50, and Pedi 70 responders at 6 months were 27.7%,
Table 3. Spearman’s correlation between the composite disease activity scores and the juvenile
idiopathic arthritis outcome measures not included in the scores on cross-sectional data*
JADAS-71 JADAS-27 JADAS-10 DAS28 CDAI
Clinic patients
Parent pain assessment 0.73 0.72 0.73 0.61 0.64
C-HAQ score 0.50 0.50 0.51 0.51 0.46
Swollen joint count 0.82 0.81 0.82 – –
Tender joint count 0.73 0.71 0.73 – –
Restricted joint count 0.78 0.76 0.77 0.71 0.72
CRP level 0.52 0.53 0.52 0.54 0.46
HRQOL study
Parent pain assessment 0.60 0.61 0.62 0.55 0.61
C-HAQ score 0.56 0.56 0.57 0.52 0.56
Swollen joint count 0.77 0.75 0.76 – –
Tender joint count 0.69 0.67 0.69 – –
Restricted joint count 0.64 0.62 0.62 0.59 0.60
Methotrexate trial†
Parent pain assessment 0.38 0.41 0.53 0.38 0.31
C-HAQ score 0.47 0.50 0.52 0.44 0.42
Swollen joint count 0.68 0.63 0.44 – –
Tender joint count 0.64 0.57 0.50 – –
Restricted joint count 0.61 0.56 0.40 0.49 0.63
Meloxicam/naproxen trial†
Parent pain assessment – – –
C-HAQ score 0.34 0.33 0.34 0.28 0.36
Swollen joint count 0.67 0.65 0.63 – –
Tender joint count 0.66 0.62 0.63 – –
Restricted joint count 0.66 0.64 0.63 0.57 0.65
* C-HAQ  Childhood Health Assessment Questionnaire; CRP  C-reactive protein; HRQOL  health-related
quality of life. See Table 1 for additional definitions.
† At baseline.
Table 4. Spearman’s correlation between the baseline–end point changes in the composite
disease activity scores and C-HAQ scores in the MTX and meloxicam/naproxen trials*
Trial (no. patients) JADAS-71 JADAS-27 JADAS-10 DAS28 CDAI
MTX (490)
C-HAQ score 0.46 0.50 0.51 0.44 0.44
DAS28 0.78 0.80 0.79 – –
CDAI 0.88 0.86 0.72 – –
Meloxicam/naproxen trial (204)
C-HAQ score 0.44 0.43 0.45 0.35 0.39
DAS28 0.74 0.74 0.70 – –
CDAI 0.87 0.86 0.75 – –
* C-HAQ  Childhood Health Assessment Questionnaire; MTX  methotrexate. See Table 1 for additional
definitions.
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11.8%, 22.7%, and 37.8%, respectively. In the meloxicam/
naproxen trial, the percentages were 38.3%, 13.3%,
17.3%, and 31.2%, respectively. The changes in the 3
JADAS versions and in the DAS28 and CDAI in relation to
the ACR Pedi 30, Pedi 50, and Pedi 70 response in the
MTX trial are shown in Figure 1. All JADAS versions
discriminated significantly between the ACR Pedi 30, Pedi
50, and Pedi 70, and their discriminant validity was com-
parable with that of the DAS28 and CDAI. However,
Dunn’s post hoc test revealed that only the JADAS-10
discriminated between ACR Pedi 30 and ACR Pedi 50
responses (P  0.05). Similar findings were obtained for
the meloxicam/naproxen trial (data not shown).
Responsiveness to clinical change and score distribu-
tion. The SRMs for the 3 JADAS versions, the DAS28,
and the CDAI in the MTX and meloxicam/naproxen
trials are shown in Table 5. All composite scores re-
vealed strong responsiveness to clinical change, with
SRM values above 0.8. The responsiveness of JADAS
and RA composite scores was comparable, although the
JADAS-10 proved slightly superior. However, a subana-
lysis of the nonresponders in the MTX and meloxicam/
naproxen trials showed that the JADAS-27 was slightly
more responsive than the JADAS-10 (data not shown).
The JADAS-10 and DAS28 revealed the best score dis-
tribution, with values of skewness and kurtosis close to
Figure 1. Comparison of the ability of the composite disease activity scores to discriminate
between different levels of American College of Rheumatology (ACR) Pediatric 30 (ACRp-30),
ACRp-50, and ACRp-70 response in the methotrexate trial (n  490). Boxplots are the means, SEs,
and 95% confidence intervals (95% CIs) of composite disease activity score values in patients
grouped by ACRp response category. The number of nonresponders and ACR 30%, 50%, and 70%
responders were 136, 58, 111, and 185, respectively. JADAS-71  Juvenile Arthritis Disease
Activity Score in 71 joints; DAS28  Disease Activity Score in 28 joints; CDAI  Clinical Disease
Activity Index.
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zero in most data sets, followed by the JADAS-27 (data
not shown).
DISCUSSION
This study describes the development and validation of a
new composite disease activity score for JIA. This score
combines information from 2 physician-centered mea-
sures (physician global assessment and active joint count),
1 parent/patient-centered measure (parent/patient global
assessment), and 1 acute-phase reactant (ESR) into a con-
tinuous measure of inflammation.
The clinical measures included in the JADAS are part of
the ACR Pedi 30, Pedi 50, and Pedi 70 core set of outcome
variables (2). These variables were identified through a
comprehensive statistical and consensus formation pro-
cess, which involved a large number of international ex-
perts, and are universally recognized as the central mea-
sures of disease activity in all phenotypes of JIA. The
choice of the 4 variables to be incorporated into the JADAS
was based on the review of the existing literature and
agreed upon by a panel of 9 pediatric rheumatologists with
a wide range of clinical experience. Inclusion of the se-
lected variables was supported by principal component
analysis. Altogether, these processes ensure the face and
content validity of the instrument.
The score of the JADAS results from the arithmetic sum
of the scores of each individual component, which makes
its calculation simple and quick. The physician and par-
ent/patient global assessments are both measured on a
0–10-cm VAS. To reduce the potential that joint count
might dominate the index, the 27-joint reduced count was
selected for inclusion in the JADAS. This count has been
found to be a valid surrogate for the whole joint count in
JIA (15). However, because the active joint count is of
primary importance in the definition of JIA activity, the
validity of the JADAS-27 was compared with that of 2
additional versions: the whole 71-joint count and the 10-
joint reduced count. To avoid giving the acute-phase reac-
tant an excessive weight in the index, the ESR value was
converted to a 0–10 scale with a simple formula that does
not require a computer or calculator.
To provide an adequate strength to the validation pro-
cess, the construct validity, discriminant validity, and re-
sponsiveness to clinical change of the JADAS were as-
sessed using 4 patient samples including 4,500 patients
from several different countries. These patients are likely
to be representative of the whole spectrum of JIA severity.
The JADAS demonstrated good construct validity in
cross-sectional samples by yielding strong correlations
with JIA activity measures not included in the score, such
as the swollen and tender joint counts, and moderate cor-
relation with the C-HAQ. Correlations were similar across
patient samples, which indicate that the index may be
robust enough to cover all phenotypes of JIA and levels of
disease activity. Correlations obtained for the 3 JADAS
versions were comparable, but superior to those yielded by
the DAS28 and CDAI. This suggests that the RA composite
scores are not equally as reliable as JADAS in capturing the
level of disease activity in children with JIA. In the 2
clinical trials, the change in JADAS was moderately cor-
related with the change in C-HAQ score, and strongly
correlated with the changes in DAS28 and CDAI score.
Correlations of RA composite scores with C-HAQ scores
were lower than those with the JADAS. Further evidence
of construct validity of the JADAS was provided by the
demonstration that its area under the curve predicted dis-
ease outcome, measured as radiographic progression over
3 years. This led us to establish that the JADAS has good
predictive validity.
The JADAS discriminated well between ACR Pedi 30,
Pedi 50, and Pedi 70 response in the 2 clinical trials; that
is, proportionately greater changes in the JADAS corre-
sponded with nonresponse and ACR Pedi 30, Pedi 50, and
Pedi 70 response levels. The discriminative ability of the
JADAS was comparable with that of the DAS28 and CDAI.
Responsiveness of the JADAS to change in the 2 clinical
trials was good (all SRM values 0.8) and was similar to
that of the DAS28 and CDAI.
This study has some potential limitations. In validation
analyses, only the parent global assessment could be as-
sessed because the patient self-reporting was not available.
However, using only parents’ proxy reports instead of both
parents’ and patients’ self-reports fails to capture the fact
that parents and children may differ in their perception of
health (25,26). Other parent-centered measures, such as
functional assessment, could be equally important in the
measurement of JIA activity. We found that versions of the
JADAS including the C-HAQ (27) or the physical function
scale of the Child Health Questionnaire (28) instead of the
parent global assessment performed similarly to the origi-
nal JADAS (data not shown).
We did not attempt to create different composite scores
for the various subsets of JIA. However, although the score
was designed to be robust enough to cover all categories of
JIA, a thorough assessment of disease activity in children
with systemic JIA requires quantification of extraarticular
manifestations, particularly fever and rash (29). The study
results might not be extrapolated to the categories of RF-
positive polyarthritis, psoriatic arthritis, and enthesitis-
related arthritis, which were excluded from 3 of 4 patient
samples. A subanalysis in MTX trial patients revealed that
the statistical performance of the 3 JADAS versions was
comparable in the main JIA subtypes (systemic, RF-nega-
tive polyarthritis, and extended oligoarthritis; data not
shown).
Another study limitation is the omission of assessment
Table 5. Responsiveness of composite disease activity






JADAS-71 1.17 (1.05–1.29) 0.89 (0.67–1.07)
JADAS-27 1.27 (1.14–1.39) 0.98 (0.84–1.11)
JADAS-10 1.29 (1.18–1.41) 1.04 (0.90–1.18)
DAS28 1.23 (1.12–1.34) 0.89 (0.75–1.03)
CDAI 1.06 (0.95–1.17) 0.93 (0.76–1.07)
* Values are the standardized response mean (95% confidence in-
terval). See Table 1 for definitions.
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of ocular disease, which is an important feature of disease
activity in JIA. However, the study panel did not include
this clinical manifestation because no standardized grad-
ing of its activity is available. We recognize that 3 of the 4
data sets were also used for the development and valida-
tion of reduced joint counts (15), raising the possibility of
bias. However, the statistical performance of 3 of the 5
joint counts investigated in that study has been revaluated
with additional analyses. Although the JADAS revealed
satisfactory discriminant validity, this property needs to
be further scrutinized by determining the minimum clin-
ically important difference. Statistical performances of the
JADAS-27 were comparable with those provided by the
JADAS-71. However, assessment of 27 joints is more fea-
sible and less tedious than evaluation of 71 joints. The
simplest, 10-joint reduced count revealed the best discrim-
inating validity, responsiveness (though not in nonre-
sponder patients), and distribution, but had a somewhat
poorer construct validity. The greater responsiveness of
this joint count may be explained by most JIA patients
having few joints involved. Use of this reduced count,
which does not enable a precise assessment of joint dis-
ease and may limit the ability to detect new joint involve-
ment over time, is advised only for use in retrospective
studies, when the total number of involved joints is
known, but no information on the individual affected
joints is available. We could only test ESR because CRP
values were available only in 1 database. However, CRP is
a direct measure of the acute-phase response and is less
confounded by other factors, including intercurrent infec-
tions, compared with ESR. Therefore, a version of the
JADAS including CRP levels instead of ESR is worth test-
ing in the future.
In conclusion, we have developed a new composite
disease activity score for JIA, which is based on the simple
arithmetic sum of 4 clinical measures. The instrument was
found to be feasible and to possess both face and content
validity; furthermore, it exhibited good construct validity,
discriminant validity, and responsiveness to clinically im-
portant change in a large population of patients. By docu-
menting these key measurement properties, we have
shown that the JADAS is a valid instrument for the assess-
ment of disease activity in JIA and is, therefore, potentially
applicable in standard clinical care, observational studies,
and clinical trials.
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